Clinical Trials for Pancreas Cancer

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with unresectable primary or metastatic liver tumors (up to 5 lesions), including those ≥3 cm or adjacent to major vessels/critical structures, adequate hepatic function (not Child-Pugh C), and no active infection receive percutaneous, image-guided high dose-rate brachytherapy using iridium-192. The therapy delivers conformal ablative radiation via temporary intratumoral catheters and is compared to a matched historical cohort for local control and survival outcomes.

ClinicalTrials.gov ID: NCT05053555

Photodynamic Priming to Facilitate Immunologic Activity of Anti-PD1 in Patients With Pancreatic Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with unresectable, locally advanced or metastatic pancreatic ductal adenocarcinoma after first-line failure (ECOG 0–1) receive intratumoral photodynamic priming with verteporfin (photosensitizer activated by light to disrupt tumor/stroma and augment antigen release) followed by pembrolizumab (anti–PD-1) plus standard mFOLFIRINOX. Excludes active autoimmune disease and significant infections; primary endpoint is iRECIST ORR.

ClinicalTrials.gov ID: NCT06381154

A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Pancreatic Cancer and Peritoneal Metastasis

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with pancreatic adenocarcinoma limited to the peritoneum (PCI ≤7) or positive peritoneal cytology after response to preoperative systemic therapy (ECOG 0–2) undergo cytoreductive surgery with intraoperative HIPEC using intraperitoneal nab-paclitaxel (albumin-bound paclitaxel; microtubule stabilizer) plus cisplatin (DNA crosslinker), with up to five additional HIPEC sessions as appropriate. Excludes extra-peritoneal metastases and requires adequate organ function.

ClinicalTrials.gov ID: NCT04858009

A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Single-arm study in adults with inoperable locally advanced or borderline resectable pancreatic adenocarcinoma, untreated and eligible for mFOLFIRINOX. Patients receive mFOLFIRINOX plus investigational Acoustic Cluster Therapy (IV PS101 microbubble–microdroplet clusters with focused ultrasound to transiently increase tumor vascular permeability and enhance intratumoral chemo delivery) every 2 weeks for up to 8 cycles.

ClinicalTrials.gov ID: NCT06850623

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with metastatic pancreatic adenocarcinoma harboring germline BRCA1/2 mutations and stable/responding disease after ≥16 weeks of first-line platinum chemotherapy receive maintenance olaparib alone versus olaparib plus pembrolizumab. Olaparib is a PARP inhibitor exploiting HRD in BRCA-mutant tumors; pembrolizumab is a PD-1 inhibitor added investigationally to assess incremental benefit.

ClinicalTrials.gov ID: NCT04548752

A Phase 1 Open-label Study to Assess the Safety and Tolerability of Zolbetuximab (IMAB362) in Combination With Chemotherapy (mFOLFIRINOX) in Participants With CLDN18.2 Positive Metastatic Pancreatic Adenocarcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with previously untreated, metastatic pancreatic adenocarcinoma that is centrally confirmed CLDN18.2-positive (≥75% membranous staining), ECOG 0–1, receive zolbetuximab (anti-CLDN18.2 mAb mediating ADCC/CDC) added to standard mFOLFIRINOX. Prior adjuvant/neoadjuvant therapy allowed if relapse ≥6 months; key exclusions include DPD deficiency, significant cardiac disease, active autoimmune disease requiring treatment, grade ≥2 neuropathy, and use of strong CYP3A/UGT1A1 modulators with irinotecan.

ClinicalTrials.gov ID: NCT06396091

A Pilot Study of Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with untreated metastatic pancreatic adenocarcinoma (ECOG 0–2) receive standard gemcitabine plus nab-paclitaxel given on a staggered, biologically optimized schedule (gemcitabine days 1/15; nab-paclitaxel days 3/17 of 28-day cycles). The investigational aspect is infusion timing/separation to enhance antitumor activity; no novel agents are used.

ClinicalTrials.gov ID: NCT04115163

A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Single-arm belzutifan monotherapy for adolescents/adults with advanced/metastatic PPGL, pNET, VHL disease–associated localized tumors, wild-type GIST, or other solid tumors with HIF-2α–related alterations; includes ≥12 years (≥18 for VHL cohort) able to take oral therapy and excludes significant hypoxia/cardiac issues. Belzutifan is an oral selective HIF-2α inhibitor that blocks HIF-2α/HIF-1β dimerization; treatment is continuous until progression/toxicity with anemia/hypoxia as key AEs to monitor.

ClinicalTrials.gov ID: NCT04924075

Phase I Pilot Study of Endoscopic Ultrasound Guided RFA in Advanced Pancreatic Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with locally advanced, unresectable, non-metastatic PDAC (ECOG 0–2) progressing after first-line therapy receive ongoing second- or third-line chemotherapy plus endoscopic ultrasound–guided radiofrequency ablation (EUS-RFA) of 1–4 cm, endoscopically accessible tumors. EUS-RFA is a local thermal ablation delivered via EUS needle to induce coagulative necrosis, performed over three sessions alongside systemic therapy to assess safety/tolerability.

ClinicalTrials.gov ID: NCT05723107

Phase II Trial of Lenvatinib-Pembrolizumab Maintenance Therapy in Patients With Advanced Unresectable Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with unresectable, advanced pancreatic ductal adenocarcinoma who have achieved at least stable disease after ≥16 weeks of first- or second-line chemotherapy receive maintenance pembrolizumab (anti–PD-1) plus lenvatinib (oral multikinase inhibitor of VEGFR/FGFR/PDGFR/RET/KIT). Single-arm maintenance approach aims to prolong disease control; excludes prior checkpoint inhibitor therapy and requires ECOG 0–1 and adequate organ function.

ClinicalTrials.gov ID: NCT04887805